Today, Vertex Pharmaceuticals Inc. announced positive Phase 3 clinical trial data for Trikafta® (elexacaftor/tezacaftor/ivacaftor) in children 6-11 years old with cystic fibrosis.
Site Search
Legislation Would Remove Financial Penalties for Participating in Research Studies
The Cystic Fibrosis Foundation has launched a new program that will fund 60 additional research coordinators to help speed the progress of CF clinical trials throughout its Therapeutics Development Network (TDN).
New Bill Would Remove Financial Penalties for Participating in Research Studies
This morning, Vertex Pharmaceuticals announced the results from the Phase 3 clinical trials of ivacaftor (Kalydeco™) and lumacaftor (VX-809) in people with two copies of the F508del mutation.
You can best manage your health when you know what to expect, what resources you can use, and a community of people with whom you can share your experiences.
There are two main types of clinical studies in CF research. Both are important to move research forward and provide the best outcomes for people with CF.
The additional funding will support a Phase 2 clinical trial for an inhaled antisense oligonucleotide drug for people with cystic fibrosis who have the splicing mutation 3849+10Kb C-to-T.
Have questions about clinical trials? The Clinical Trial Navigator is a person who can help you get the answers you need.